[NOTICE: This Consolidated Financial Summary is a translation of the Japanese original for reference purposes only, and in the event of any discrepancy, the Japanese original shall prevail.]

Consolidated Financial Summary under Japanese GAAP for the First Nine Months of the Fiscal Year Ending September 30, 2026

August 14, 2026

Company Name: Amvis Holdings, Inc.
Stock Exchange Listings: Tokyo
Code Number: 7071
URL: https://www.amvis.com/en/
Representative: Keiichi Shibahara, Representative Director and CEO
For Inquiry: Shingo Yamaguchi, Director TEL: +81-3-6262-5105
Dividend Payment Date: -
Supplementary Information for Financial Statements: Available
Explanatory Meeting to Be Held: No

(Amounts of less than one million yen are truncated)

1. Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending September 30, 2026

(1) Consolidated Operating Results (% represents the change from the previous fiscal year)

	Net Sales		EBITDA		Operating Profit		Ordinary Profit		Profit Attributable to Owners of Parent	
Nine Months Ended	million yen	%	million yen	%	million yen	%	million yen	%	million yen	%
June 30, 2026	38,288	5.3	6,157	(8.1)	3,623	(22.9)	3,681	(23.9)	2,485	(17.1)
June 30, 2025	36,364	18.4	6,701	(29.2)	4,697	(42.4)	4,838	(40.6)	2,998	(47.8)

Notes
1. Comprehensive Income
   Nine months ended June 30, 2026: 2,488 million yen / (17.0%)
   Nine months ended June 30, 2025: 2,998 million yen / (47.8%)
2. EBITDA = Operating Profit + Depreciation + Amortization of Goodwill + Share-Based Compensation Expenses

	Earnings per Share	Diluted Earnings per Share
Nine Months Ended	yen	yen
June 30, 2026	25.41	25.40
June 30, 2025	30.73	30.73

(2) Consolidated Financial Position

	Total Assets	Total Net Assets	Shareholders' Equity Ratio
As of	million yen	million yen	%
June 30, 2026	78,555	38,555	49.0
September 30, 2025	83,947	36,132	43.0

Reference: Shareholders' Equity
As of June 30, 2026: 38,508 million yen
As of September 30, 2025: 36,132 million yen

2. Dividends on Common Stock

	Dividends per Share				
	1st quarter end	2nd quarter end	3rd quarter end	Fiscal year end	Annual
	yen	yen	yen	yen	yen
Fiscal Year Ended September 30, 2025	–	0.00	–	4.00	4.00
Fiscal Year Ending September 30, 2026	–	0.00			
Forecast			–	4.00	4.00

Notes
Revision of the forecast from most recently announced figures: No

3. Consolidated Earnings Forecasts for the Fiscal Year Ending September 30, 2026

(% represents the change from the previous fiscal year)

	Net Sales		EBITDA		Operating Profit		Ordinary Profit		Profit Attributable to Owners of Parent		Earnings per Share
	million yen	%	million yen	%	million yen	%	million yen	%	million yen	%	yen
Fiscal Year Ending September 30, 2026	51,700	5.1	7,100	(20.8)	3,800	(38.3)	3,300	(48.0)	2,100	(42.6)	21.53

Notes

Revision of the forecast from most recently announced figures: No

Notes

1. Significant changes in the scope of consolidation: No
2. Application of special accounting methods for the preparation of the Quarterly Consolidated Financial Statements: Yes
3. Changes in Accounting Policies, Changes in Accounting Estimates and Restatements

(A) Changes in accounting policies due to revision of accounting standards: No

(B) Other changes in accounting policies: No

(C) Changes in accounting estimates: No

(D) Restatement of corrections: No

4. Number of shares outstanding (common shares)

(A) Total shares outstanding including treasury shares

As of June 30, 2026	98,112,000 shares
As of September 30, 2025	98,112,000 shares

(B) Treasury shares

As of June 30, 2026	58,857 shares
As of September 30, 2025	578,157 shares

(C) Average outstanding shares

Nine months ended June 30, 2026	97,831,330 shares
Nine months ended June 30, 2025	97,568,361 shares

This report is not subject to review by certified public accountants or an audit firm.

Notes for using earnings forecasts in this report and others

Disclaimer regarding forward-looking information including appropriate use of forecast financial results

This report contains forward-looking statements, such as earnings forecasts, regarding the intent, beliefs and current expectations of Amvis Holdings, Inc. (hereinafter referred to as the “Company”) and its management with respect to the expected financial position and results of operations of the Company. Actual performance and results may differ from those forecasts due to various factors.

Table of Contents of Appendix

1. Consolidated Operating Results

(1) Overview of Consolidated Operating Results

The Group has set forth the vision of becoming "the world's most exciting medical and healthcare company," aiming to create second and third core businesses following the Ishinkan business and to build a company that will prosper for the next 100 years. During the nine months ended June 30, 2026, the Group opened eight new facilities under the Ishinkan business (Saitama: 1, Chiba: 1, Tokyo: 3, Kanagawa: 1, Mie: 1, Osaka: 1), while transferring the operations of Ishinkan Kurashiki to another operator. Going forward, the Group will continue to proactively open new facilities based on detailed marketing and facility opening strategies, while also actively conducting sales activities targeting medical institutions and other referral sources.

In recent years, the Group has leveraged the expertise and know-how accumulated through the operation of Ishinkan facilities and has fully entered the comprehensive medical support business, steadily building a track record of providing management support services to medical institutions during the nine months ended June 30, 2026. Going forward, the Group will expand its initiatives beyond local and depopulated areas to provide comprehensive management support to a wide range of medical institutions, including general hospitals and post-acute care hospitals. The Group will continue to be a hungry challenger, boldly questioning conventional practices and exploring innovative solutions to create lasting value, while envisioning an ambitious future. As a result, the operating results for the Group for the nine months ended June 30, 2026, are as follows.

[Operating Results for the Nine Months Ended June 30, 2026]

(Unit: million yen)

	Nine Months Ended June 30, 2025	Nine Months Ended June 30, 2026	Change	Percentage Change
Net Sales	36,364	38,288	+1,923	+5.3%
EBITDA	6,701	6,157	(543)	(8.1%)
Operating Profit	4,697	3,623	(1,074)	(22.9%)
Ordinary Profit	4,838	3,681	(1,157)	(23.9%)
Profit Attributable to Owners of Parent	2,998	2,485	(512)	(17.1%)

(Note) EBITDA = Operating Profit + Depreciation + Amortization of goodwill + Share-based compensation expenses

Operating results by segment are as follows.

From the first quarter of the current fiscal year, the Group has changed its reportable segments from a single segment to two segments: "Ishinkan" and "Comprehensive Medical Support," as it was determined that this classification better reflects the Group's management structure, resource allocation, and future growth strategy. The following year-on-year comparisons are based on the figures for the nine months ended June 30, 2025, which have been reclassified into the new segment structure. For details, please refer to "2. Quarterly Consolidated Financial Statements and Principal Notes, (3) Notes Regarding Quarterly Consolidated Financial Statements (Segment Information, etc.)."

[Operating Results by Segment for the First Nine Months]

(Unit: million yen)

Segment	Item	Nine Months Ended June 30, 2025	Nine Months Ended June 30, 2026	Change	Percentage Change
Ishinkan	Net Sales	35,976	37,393	+1,416	+3.9%
	Segment Profit	4,565	3,023	(1,542)	(33.8%)
Comprehensive Medical Support	Net Sales	388	897	+509	+131.1%
	Segment Profit	131	599	+468	+356.4%

Notes

1. Net sales represent net sales of each segment.
2. Segment profit represents operating profit of each segment.

(A) Ishinkan Business

In the Ishinkan Business, although the facility occupancy rate temporarily declined due to the impact of responding to the Special Investigation Committee, net sales were 37,393 million yen (up 3.9% year-on-year) primarily driven by the ramp-up of facilities opened in the previous fiscal year.
On the other hand, the gross profit margin declined due to the impact of proactive staffing associated with the opening of new facilities and an increase in personnel expenses aimed at securing human resources, resulting in a segment profit of 3,023 million yen (down 33.8% year-on-year).

(B) Comprehensive Medical Support Business
In the Comprehensive Medical Support Business, net sales were 897 million yen (up 131.1% year-on-year) due to factors such as the addition of two medical institutions receiving management support and the expansion of services provided to existing support recipients.
On the other hand, although an allowance for doubtful accounts of JPY 35 million was recorded for some business partners, segment profit was 599 million yen (up 356.4% year-on-year) due to the increase in net sales.

As a result, the Group's performance for the nine months ended June 30, 2026 was as follows: net sales of 38,288 million yen (up 5.3% year-on-year), operating profit of 3,623 million yen (down 22.9% year-on-year), ordinary profit of 3,681 million yen (down 23.9% year-on-year), and profit attributable to owners of parent of 2,485 million yen (down 17.1% year-on-year).

(2) Overview of Financial Position
(A) Status of Assets, Liabilities and Net Assets
(Assets)
Total assets as of June 30, 2026 were 78,555 million yen, a decrease of 5,391 million yen from the end of the previous fiscal year. This was mainly due to a decrease of 7,565 million yen in cash and deposits due to the repayment of borrowings, despite an increase of 2,474 million yen in property, plant and equipment associated with the opening of new facilities.

(Liabilities)
Total liabilities as of June 30, 2026 were 40,000 million yen, a decrease of 7,814 million yen from the end of the previous fiscal year. This was mainly due to a decrease of 7,982 million yen in borrowings due to repayments.

(Net assets)
Net assets as of June 30, 2026 were 38,555 million yen, an increase of 2,422 million yen from the end of the previous fiscal year. This was mainly due to an increase in retained earnings resulting from the recording of 2,485 million yen in profit attributable to owners of parent, as well as a decrease of 744 million yen in treasury shares due to the disposal of treasury shares associated with the granting of restricted stock.

(3) Explanation of Forward-Looking Statements of Consolidated Results Forecasts
Regarding the consolidated earnings forecast for the fiscal year ending September 30, 2026, there are no changes from the full-year consolidated earnings forecast disclosed in the "Consolidated Financial Summary for the Fiscal Year Ended September 30, 2025" on November 6, 2025.

2. Quarterly Consolidated Financial Statements and Principal Notes

(1) Quarterly Consolidated Balance Sheets

(Unit: million yen)

	As of September 30, 2025	As of June 30, 2026
Assets		
Current Assets		
Cash and Deposits	10,833	3,267
Accounts Receivable	9,191	9,066
Inventories	30	45
Other	1,855	1,724
Allowance for Doubtful Accounts	(171)	(209)
Total Current Assets	21,738	13,894
Non-Current Assets		
Property, Plant and Equipment		
Buildings and Structures, Net	43,979	45,536
Machinery, Equipment and Vehicles, Net	4	2
Tools, Furniture and Fixtures, Net	202	226
Leased Assets, Net	7,914	9,019
Land	2,471	3,272
Construction in Progress	2,592	1,581
Total Property, Plant and Equipment	57,165	59,639
Intangible Assets		
Other	185	166
Total Intangible Assets	185	166
Investments and Other Assets		
Leasehold and Guarantee Deposits	3,570	3,556
Deferred Tax Assets	851	817
Other	436	481
Total Investments and Other Assets	4,857	4,855
Total Non-Current Assets	62,208	64,661
Total Assets	83,947	78,555

(Unit: million yen)

	As of September 30, 2025	As of June 30, 2026
Liabilities		
Current Liabilities		
Accounts Payable	149	186
Short-Term Borrowings	7,699	-
Current Portion of Long-Term Borrowings	4,763	5,208
Lease Obligations	202	238
Other Payables and Accrued Expenses	3,748	2,929
Income Taxes Payable	433	253
Provision for Bonuses	1,310	1,506
Other	1,137	825
Total Current Liabilities	19,444	11,148
Non-Current Liabilities		
Long-Term Borrowings	19,277	18,549
Lease Obligations	8,210	9,361
Provision for Litigation Losses	11	-
Asset Retirement Obligations	639	656
Net Defined Benefit Liability	66	83
Other	164	200
Total Non-Current Liabilities	28,369	28,852
Total Liabilities	47,814	40,000
Net Assets		
Shareholders’ Equity		
Share Capital	66	66
Capital Surplus	11,641	11,175
Retained Earnings	25,187	27,282
Treasury Shares	(750)	(5)
Total Shareholders’ Equity	36,145	38,519
Accumulated Other Comprehensive Income		
Remeasurements of Defined Benefit Plans	(12)	(10)
Total Accumulated Other Comprehensive Income	(12)	(10)
Stock Acquisition Rights	-	46
Total Net Assets	36,132	38,555
Total Liabilities and Net Assets	83,947	78,555

(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive Income

[Quarterly Consolidated Statements of Income]

(Unit: million yen)

	Nine Months Ended June 30, 2025	Nine Months Ended June 30, 2026
Net Sales	36,364	38,288
Cost of Sales	25,131	28,135
Gross Profit	11,233	10,152
Selling, General and Administrative Expenses	6,536	6,529
Operating Profit	4,697	3,623
Non-Operating Income		
Subsidy Income	387	473
Gain on Sale of Investments	149	-
Miscellaneous Income	31	136
Total Non-Operating Income	568	609
Non-Operating Expenses		
Interest Expense	415	504
Miscellaneous Loss	12	47
Total Non-Operating Expenses	427	551
Ordinary Profit	4,838	3,681
Extraordinary Income		
Gain on Transfer of Business	-	34
Total Extraordinary Income	-	34
Extraordinary Losses		
Loss on retirement of non-current assets	-	14
Special investigation expenses, etc.	199	-
Provision for special investigation expenses	354	-
Total Extraordinary Losses	553	14
Profit Before Income Taxes	4,285	3,701
Income Taxes	1,286	1,215
Profit	2,998	2,485
Profit Attributable to Non-Controlling Interests	-	-
Profit Attributable to Owners of Parent	2,998	2,485

[Quarterly Consolidated Statements of Comprehensive Income]

(Unit: million yen)

	Nine Months Ended June 30, 2025	Nine Months Ended June 30, 2026
Profit	2,998	2,485
Other Comprehensive Income		
Remeasurements of Defined Benefit Plans	0	2
Total Other Comprehensive Income	0	2
Comprehensive Income	2,998	2,488
(Details)		
Attributable to Owners of Parent	2,998	2,488
Attributable to Non-Controlling Interests	-	-

(3) Notes Regarding Quarterly Consolidated Financial Statements

(Changes in the Scope of Consolidation or Application of the Equity Method)

Not applicable.

(Changes in Accounting Policies)

Not applicable.

(Adoption of Specific Accounting Methods for the Preparation of Quarterly Consolidated Financial Statements)

Tax Expense Calculations

Tax expense is calculated by applying an estimated effective tax rate for the full fiscal year to profit before income taxes for the nine-month period under review.

(Segment Information)

I. Nine Months Ended June 30, 2025 (From October 1, 2024 to June 30, 2025)

1. Information on net sales and profit by reportable segment

(Unit: million yen)

	Reportable segments			Adjustments	Amounts in the quarterly consolidated statements of income (Note)
	Ishinkan	Comprehensive Medical Support	Total		
Net Sales					
Net Sales to External Customers	35,976	388	36,364	-	36,364
Inter-segment Net Sales or Transfers	-	-	-	-	-
Total	35,976	388	36,364	-	36,364
Segment Profit	4,565	131	4,697	-	4,697

(Note) Segment profit is reconciled to operating profit in the quarterly consolidated statements of income through adjustments.

II. Nine Months Ended June 30, 2026 (From October 1, 2025 to June 30, 2026)

1. Information on net sales and profit or loss by reportable segment

(Unit: million yen)

	Reportable segments			Adjustments	Amounts in the quarterly consolidated statements of income (Note)
	Ishinkan	Comprehensive Medical Support	Total		
Net Sales					
Net Sales to External Customers	37,393	895	38,288	-	38,288
Inter-segment Net Sales or Transfers	-	2	2	(2)	-
Total	37,393	897	38,291	(2)	38,288
Segment Profit	3,023	599	3,623	-	3,623

(Note) Segment profit is reconciled to operating profit in the quarterly consolidated statements of income through adjustments.

2. Matters Concerning Changes in Reportable Segments

As the Group previously operated as a single segment, the Ishinkan business, disclosure of segment information was omitted. However, from the first quarter of the current fiscal year, following a review of management control classifications, the Group has disclosed its reportable segments by classifying them into “Ishinkan” and “Comprehensive Medical Support.”

Segment information for the first nine months of the previous fiscal year is also disclosed based on the revised classification of reportable segments.

(Significant Changes in Shareholders’ Equity)

Not applicable.

(Going Concern Assumption)

Not applicable.

(Note on the Non-Preparation of a Quarterly Consolidated Statement of Cash Flows)

A quarterly consolidated statement of cash flows has not been prepared for the nine months ended June 30, 2026. Depreciation (including amortization of intangible assets) and amortization of goodwill for the nine months ended June 30, 2026, are as follows.

	Nine Months Ended June 30, 2025	Nine Months Ended June 30, 2026
Depreciation	1,974 million yen	2,425 million yen
Amortization of goodwill	4 million yen	17 million yen